Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest update is out from PW Medtech Group Ltd. ( (HK:1358) ).
Sichuan Ruijian Medical, a subsidiary of PW Medtech Group, reported a 17.6% increase in revenue for the year ending December 31, 2024, compared to the previous year. However, profits decreased due to reduced government subsidies, increased share-based compensation, and higher professional fees related to a spin-off listing. The company’s financial health remains strong with a significant increase in total assets and equity, indicating robust growth and stability.
More about PW Medtech Group Ltd.
PW Medtech Group Ltd., incorporated in the Cayman Islands, is primarily engaged in the research and development, manufacturing, and sales of advanced medical devices. Their product range includes infusion sets, intravenous cannula products, insulin needles, blood purification devices, and regenerative medical biomaterials in China. Sichuan Ruijian Medical, a subsidiary, focuses on medical devices for blood purification.
YTD Price Performance: -8.18%
Average Trading Volume: 5,446
Technical Sentiment Consensus Rating: Sell
Current Market Cap: €181.7M
For detailed information about 1358 stock, go to TipRanks’ Stock Analysis page.